HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of standard of care treatment with a low steroid and mycophenolate mofetil regimen for lupus nephritis in the ALMS and AURA studies.

Abstract
Lupus nephritis is the most common organ-threatening manifestation of systemic lupus erythematosus. The current standard of care for patients is treatment with a combination of steroids plus either mycophenolate mofetil (MMF) or cyclophosphamide. However, these medications are associated with considerable toxicity and suboptimal efficacy. This retrospective propensity analysis of data from 63 matched patients enrolled in two of the largest active lupus nephritis controlled trials, ALMS and AURA, suggests that the high dose regimen of MMF and steroids as described in the 2012 American College of Rheumatology lupus nephritis guidelines may not be necessary in all lupus nephritis patients. A lower dose regimen may result in better long-term safety, including a reduction in lymphoproliferative disorders, skin cancers and steroid related side effects, without compromising efficacy. An ongoing randomized controlled double-blind phase 3 study, AURORA (NCT03021499), is investigating renal response in 358 patients randomized to receive a low dose regimen containing voclosporin, MMF and steroid therapy as used in the AURA trial. It is anticipated that the AURORA study and its blinded two-year extension will provide important long-term outcome data.
AuthorsM Dall'Era, N Solomons, R Federico, M Truman
JournalLupus (Lupus) Vol. 28 Issue 5 Pg. 591-596 (Apr 2019) ISSN: 1477-0962 [Electronic] England
PMID31066646 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Immunosuppressive Agents
  • Steroids
  • voclosporin
  • Cyclosporine
  • Cyclophosphamide
  • Mycophenolic Acid
Topics
  • Adolescent
  • Adult
  • Aged
  • Cyclophosphamide (therapeutic use)
  • Cyclosporine (therapeutic use)
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Logistic Models
  • Lupus Nephritis (drug therapy, pathology)
  • Male
  • Middle Aged
  • Mycophenolic Acid (therapeutic use)
  • Propensity Score
  • Randomized Controlled Trials as Topic
  • Remission Induction
  • Retrospective Studies
  • Standard of Care
  • Steroids (therapeutic use)
  • Time-to-Treatment
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: